caa a22 4500 475818202 CHVBK 20180406123815.0 cr unu---uuuuu 170329e20000401xx s 000 0 eng 10.1007/s002280050719 doi (NATIONALLICENCE)springer-10.1007/s002280050719 Pharmacokinetics of intravenous ATP in cancer patients [Elektronische Daten] [H. J. Agteresch, P. C. Dagnelie, T. Rietveld, J. W. O. van den Berg, A. H. J. Danser, J. H. P. Wilson] Objective: To characterise the pharmacokinetics of adenosine 5′-triphosphate (ATP) in patients with lung cancer after i.v. administration of different ATP dosages. Methods: Twenty-eight patients received a total of 176 i.v. ATP courses of 30 h. Fifty-two infusions were given as low-dose infusions of 25-40 μg kg−1 min−1, 47 as middle-dose infusions of 45-60 μg kg−1 min−1 and 77 as high-dose infusions of 65-75 μg kg−1 min−1 ATP. Kinetic data of ATP concentrations in erythrocytes were available from 124 ATP courses. Results are expressed as mean ± SEM. Results: Most ATP courses in cancer patients were without side effects (64%), and side effects occurring in the remaining courses were mild and transient, resolving within minutes after decreasing the infusion rate. Baseline ATP concentration in erythrocytes was 1554 ± 51 μmol l−1. ATP plateau levels at 24 h were significantly increased by 53 ± 3, 56 ± 3 and 69 ± 2% after low-dose, middle-dose and high-dose ATP infusions, respectively. At the same time, significant increases in plasma uric acid concentrations were observed: 0.06 ± 0.01, 0.11 ± 0.01 and 0.16 ± 0.01 mmol l−1, respectively. The mean half-time for disappearance of ATP from erythrocytes, measured in five patients, was 5.9 ± 0.5 h. Conclusions: During constant i.v. infusion of ATP in lung cancer patients, ATP is taken up by erythrocytes and reaches dose-dependent plateau levels 50-70% above basal concentrations at approximately 24 h. Springer-Verlag Berlin Heidelberg, 2000 Key words ATP nationallicence Pharmacokinetics nationallicence Cancer nationallicence Agteresch H. J. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut Dagnelie P. C. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut Rietveld T. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut van den Berg J. W. O. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut Danser A. H. J. Department of Pharmacology, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands, NL aut Wilson J. H. P. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut https://doi.org/10.1007/s002280050719 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050719 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Agteresch H. J. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut NATIONALLICENCE 700 1- Dagnelie P. C. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut NATIONALLICENCE 700 1- Rietveld T. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut NATIONALLICENCE 700 1- van den Berg J. W. O. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut NATIONALLICENCE 700 1- Danser A. H. J. Department of Pharmacology, Erasmus University Medical Centre Rotterdam, Rotterdam, The Netherlands, NL aut NATIONALLICENCE 700 1- Wilson J. H. P. Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, NL aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer